Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abbott Laboratories
(NY:
ABT
)
118.77
-0.18 (-0.15%)
Official Closing Price
Updated: 5:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
40
41
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
February 22, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
3 Top Dividend Kings to Buy for the Long Haul
February 20, 2023
These companies have more than 150 years of dividend growth between them.
Via
The Motley Fool
2 Exceptional Growth Stocks Billionaires Keep Buying With Both Hands
February 20, 2023
A poor performance from the broad market didn't stop these billionaire hedge fund managers from placing big bets on three supercharged growth stocks.
Via
The Motley Fool
Interview With David Rolfe of Wedgewood Partners
February 17, 2023
Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe.
Via
The Motley Fool
Why Cardiovascular Systems Stock Is Soaring Today
February 09, 2023
The medtech company has agreed to a buyout offer from Abbott Laboratories.
Via
The Motley Fool
Is This Dividend King a Buy for Income Investors?
February 07, 2023
This healthcare company has one of the most established payouts in its sector.
Via
The Motley Fool
I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.
February 17, 2023
We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right?
Via
InvestorPlace
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
February 17, 2023
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors.
Via
MarketBeat
7 Hot Healthcare Stocks With the Potential to Outperform
February 15, 2023
These healthcare stocks to buy now have the potential to outperform the market over the long-term because their businesses are strong.
Via
InvestorPlace
Which Healthcare Stock Is a Better Pick in 2023?
February 14, 2023
With a potential recession on the horizon, healthcare stocks could be good picks for investors. Which of these three is best?
Via
InvestorPlace
What 5 Analyst Ratings Have To Say About Abbott Laboratories
January 26, 2023
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
February 14, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Better Buy: Johnson & Johnson or AbbVie?
February 14, 2023
The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead.
Via
The Motley Fool
Candy? Flowers? These Top Stocks Offer You Something Even Sweeter
February 14, 2023
These stocks may reward you over time.
Via
The Motley Fool
The 7 Most Undervalued Dividend Aristocrats to Buy
February 13, 2023
With so many uncertainties ahead, investors may take comfort in the stability of the most undervalued dividend aristocrats to buy.
Via
InvestorPlace
Abbott-Cardiovascular Systems Acquisition Could Further Add Uncertainty Over Surmodics' Product: Analyst Downgrades Stock
February 13, 2023
Via
Benzinga
Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million
February 09, 2023
Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and
Via
Spotlight Growth
Why Is Cardiovascular Systems (CSII) Stock Up 48% Today?
February 09, 2023
Cardiovascular Systems (CSII) stock is rising higher on Thursday following news that Abbott (ABT) intends to acquire the company.
Via
InvestorPlace
Abbott Adds Complementary Technologies To Its Vascular Offering Via Cardiovascular Systems Deal For $890M
February 09, 2023
Via
Benzinga
3 Dividend Stocks That Will Hold Up No Matter the Market Conditions
February 08, 2023
These stocks could boost your portfolio in bear markets and bull markets.
Via
The Motley Fool
Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?
February 07, 2023
The healthcare stock fell 22% last year.
Via
The Motley Fool
2 Beaten-Down Stocks With Stable Dividends to Buy In 2023
February 04, 2023
You can bet the farm on these companies' dividends.
Via
The Motley Fool
3 Unstoppable Dividend Stocks to Buy in February
February 04, 2023
All three belong to the elite group of stocks known as Dividend Kings.
Via
The Motley Fool
2 Top Dividend Growth Stocks to Buy in February
February 01, 2023
They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.
Via
The Motley Fool
5 Top Stocks to Buy Now
January 31, 2023
This eclectic mix of stocks will help diversify your portfolio.
Via
The Motley Fool
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
January 30, 2023
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.
Via
Talk Markets
GE Healthcare Technology: Speculating On Dividends
January 30, 2023
GE Healthcare released a solid report and gave steady guidance that includes ample room in the cash flow for a dividend, should the board choose to pay one.
Via
MarketBeat
Is Abbott Laboratories a Good Dividend Stock to Buy Now?
January 28, 2023
At least four Wall Street banks recently raised their price targets for the healthcare giant.
Via
The Motley Fool
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
January 27, 2023
Stocks reacted well to uneven earnings and economic reports.
Via
Investor's Business Daily
NIKE To Rally Over 23%? Here Are 10 Other Analyst Forecasts For Thursday
January 26, 2023
Keybanc raised the price target for D.R. Horton, Inc. (NYSE: DHI) from $97 to $109. Keybanc analyst Kenneth Zener maintained an Overweight rating. D.R. Horton shares fell 1.6% to close at $95.48 on...
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.